Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression

被引:104
作者
Wu, Z. L. [1 ]
Zheng, S. S. [1 ]
Li, Z. M. [1 ]
Qiao, Y. Y. [1 ,2 ]
Aau, M. Y. [1 ]
Yu, Q. [1 ,2 ]
机构
[1] ASTAR, Genome Inst Singapore, Singapore 138672, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore
关键词
EZH2; E2F1; apoptosis; epigenetics; Bim; EMBRYONIC STEM-CELLS; CANCER-CELLS; EPITHELIAL-CELLS; BREAST-CANCER; DIRECT TARGET; HISTONE H3; GENE; E2F; PATHWAY; DEATH;
D O I
10.1038/cdd.2009.162
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Deregulation of the pRB/E2F pathway, which occurs frequently in human malignancy, is often associated with inappropriate proliferation and/or apoptosis. While the role of E2F1 in apoptosis induction has been well-established, it remains unclear how this pro-apoptotic activity is regulated in cancer. Here we describe EZH2, an oncogenic polycomb histone methyltransferase and an E2F1 target, as an important regulator of E2F1-dependent apoptosis. We show that E2F1 induces EZH2 expression, which in turn antagonizes the induction of E2F1 pro-apoptotic target Bim expression. RNAi-mediated gene depletion of EZH2 enhances E2F1-dependent Bim expression, thereby promoting the pro-apoptotic activity of E2F1. Hence, the concomitant induction of EZH2 and Bim by E2F1 constitutes a fail-safe mechanism to allow tumor cells with aberrant E2F1 activity to evade apoptosis. These findings reveal a novel mechanism by which the apoptotic activity of E2F1 is restrained in human cancer and also provide the first evidence that EZH2 directly regulates apoptotic process in cancer cells. Cell Death and Differentiation (2010) 17, 801-810; doi:10.1038/cdd.2009.162; published online 6 November 2009
引用
收藏
页码:801 / 810
页数:10
相关论文
共 43 条
[1]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[2]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[3]   E2F target genes: unraveling the biology [J].
Bracken, AP ;
Ciro, M ;
Cocito, A ;
Helin, K .
TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (08) :409-417
[4]   EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J].
Adrian P. Bracken ;
Diego Pasini ;
Maria Capra ;
Elena Prosperini ;
Elena Colli ;
Kristian Helin .
The EMBO Journal, 2003, 22 (20) :5323-5335
[5]   Cellular mechanisms of tumour suppression by the retinoblastoma gene [J].
Burkhart, Deborah L. ;
Sage, Julien .
NATURE REVIEWS CANCER, 2008, 8 (09) :671-682
[6]   Repression of E-cadherin by the polycomb group protein EZH2 in cancer [J].
Cao, Q. ;
Yu, J. ;
Dhanasekaran, S. M. ;
Kim, J. H. ;
Mani, R-S ;
Tomlins, S. A. ;
Mehra, R. ;
Laxman, B. ;
Cao, X. ;
Yu, J. ;
Kleer, C. G. ;
Varambally, S. ;
Chinnaiyan, A. M. .
ONCOGENE, 2008, 27 (58) :7274-7284
[7]   The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3 [J].
Cao, R ;
Zhang, Y .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2004, 14 (02) :155-164
[8]   c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1 [J].
Cowling, Victoria H. ;
D'Cruz, Celina M. ;
Chodosh, Lewis A. ;
Cole, Michael D. .
MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (14) :5135-5146
[9]  
David J., 2000, Clin. Appl. Immunol. Rev, V1, P105
[10]   Bim is a suppressor of Myc-induced mouse B cell leukemia [J].
Egle, A ;
Harris, AW ;
Bouillet, P ;
Cory, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (16) :6164-6169